The fact
Anna Beyeler, a neurobiologist at Inserm, leads clinical research.
These treatments could be authorized by 2028 in France.
Click the link to read an article on the topic:
Anna Beyeler, a neurobiologist at Inserm, leads clinical research.
These treatments could be authorized by 2028 in France.